Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
229 Clinical Updates found
Image of a lung
MSK Clinical Research Roundup

The MSK Clinical Research Roundup keeps physicians up to date on the latest and most noteworthy patient treatments, clinical trials, and translational research happening at MSK.
David Jones, MD performing image guided surgery
A Genomic Model To Predict Recurrence of Early-Stage Lung Adenocarcinoma

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
Vivian Strong, MD in the operating room
For Patients With CDH1 Mutations, Total Gastrectomy Can Reduce Stomach Cancer Mortality Rate

Signet ring cell cancer (SRCC) was detected in the vast majority of patients with CDH1 mutations following total gastrectomy.
Urologic surgeon speaking with patient
Patients with Bladder Cancer Report Favorable Long-Term Quality of Life After Radical Cystectomy

A large cohort of patients with high-risk bladder cancer who underwent radical cystectomy and urinary tract reconstruction at Memorial Sloan Kettering Cancer Center reported favorable recovery and health-related quality of life within 24 months across most outcome measures.
HiSeq 2500 Ultra-High-Throughput Sequencing System powers MSK-IMPACT
Sequencing Cerebrospinal Fluid Is Clinically Useful in Pediatric, Adolescent, and Young Adult Brain Tumors

Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.
ASCO logo sign at meeting
MSK Research Roundup at ASCO 2022: Breakthrough Findings for Rectal Cancer, Breast Cancer, Leptomeningeal Metastasis, Pancreatic Cancer, and Lung Cancer

Memorial Sloan Kettering Cancer Center (MSK) experts presented breakthrough findings in several areas of cancer research at the 2022 Annual ASCO meeting, focusing on rectal, breast, leptomeningeal metastasis, pancreatic, and lung cancers.
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Rectal Cancer Disappears After Experimental Use of Immunotherapy

Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise

At the annual ASCO meeting, MSK medical oncologist Shanu Modi is presenting results from a clinical trial that found more people can benefit from a targeted therapy for breast cancer than previously thought.
Memorial Sloan Kettering Cancer Center Study Points to Expanded Genomic Testing that Aims To Benefit Children and Young Adults With Cancer

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Dr. Nancy Y. Lee
MSK Finds De-escalation of Radiotherapy Safely Limits Side Effects for HPV-Associated Oropharyngeal Cancer

A study by Memorial Sloan Kettering (MSK) recently published in JAMA Oncology showed that radiation dose to the elective regions can be safely de-escalated for patients with human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) who received concurrent chemotherapy.